Mycosis fungoides: successful re-treatment with brentuximab vedotin-Reference-Cited by-同舟云学术

Mycosis fungoides: successful re-treatment with brentuximab vedotin

Published:2024-03-12 Issue:6 Volume:190 Page:929-930
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:

Author:

James Mariel¹,Nakamura Mano²,Whittaker Sean¹³,Morris Stephen²

Affiliation:

1. St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust , London , UK

2. Guy’s and St Thomas’ NHS Foundation Trust , London , UK

3. King’s College London , London , UK

Abstract

UK guidelines currently endorse only one course of brentuximab vedotin as second-line treatment for CD30+ CTCL. We demonstrate that re-treatment can be safe, tolerable and highly efficacious in selected patients.

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/bjd/advance-article-pdf/doi/10.1093/bjd/ljae097/57242633/ljae097.pdf

Reference5 articles.

1. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal;Agar;J Clin Oncol,2010

2. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial;Prince;Lancet,2017

3. Response to brentuximab vedotin versus physician’s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: an ALCANZA sub-analysis;Kim;Eur J Cancer,2021

4. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin;Horwitz;Blood,2014

5. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies;Bartlett;J Hematol Oncol,2014